| Identification | Back Directory | [Name]
Bremelanotide (Acetate) | [CAS]
1607799-13-2 | [Synonyms]
189691-06-3 (free base)
α-MSH (PT-141)，Bremelanotide
PT-141 ACETATE;189691-06-3 (FREE BASE)
Bremelanotide acetate
(PT-141 acetate) | [Molecular Formula]
C52H72N14O12 | [MDL Number]
MFCD29472571 | [MOL File]
1607799-13-2.mol | [Molecular Weight]
1085.23 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 5 mg/ml | [form ]
A solid | [color ]
White to off-white | [Sequence]
Ac-[Nle}-Asp-His-{d-Phe}-Arg-Trp-Lys (Lactam bridge: Asp4-Lys7) | [InChIKey]
MAYUSRUHXFWITM-UKGCEBKRNA-N |
| Hazard Information | Back Directory | [Description]
Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction.. In Vivo: Bremelanotide Acetate (50-200 μg/kg; s.c.; once) significantly increases proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers. | [Uses]
Bremelanotide is a novel drug candidate for the treatment of male and female sexual dysfunction. Bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular effects found in ED drugs currently available. Bremelanotide works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products. | [in vivo]
Bremelanotide Acetate (50-200 μg/kg; s.c.; once) significantly increases proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers[2]. | Animal Model: | Ovariectomized Long–Evans rats[2] | | Dosage: | 50, 100, 200 μg/kg | | Administration: | s.c.; once | | Result: | Significantly increased proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers. |
| [IC 50]
MC3R; MC4R |
|
|